The 36-month beta value for NMRA is at 2.55. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for NMRA is 55.85M, and currently, shorts hold a 20.05% of that float. The average trading volume for NMRA on February 28, 2025 was 3.18M shares.
NMRA) stock’s latest price update
The stock of Neumora Therapeutics Inc (NASDAQ: NMRA) has increased by 1.29 when compared to last closing price of 1.55.Despite this, the company has seen a loss of -12.78% in its stock price over the last five trading days. globenewswire.com reported 2025-02-28 that NEW YORK, Feb. 28, 2025 (GLOBE NEWSWIRE) — Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) for violations of the federal securities laws on behalf of investors who purchased or acquired Neumora common stock at the time of the Company’s Initial Public Offering (“IPO”) on September 15, 2023.
NMRA’s Market Performance
NMRA’s stock has fallen by -12.78% in the past week, with a monthly drop of -18.65% and a quarterly drop of -83.76%. The volatility ratio for the week is 7.04% while the volatility levels for the last 30 days are 6.67% for Neumora Therapeutics Inc The simple moving average for the last 20 days is -10.44% for NMRA’s stock, with a simple moving average of -83.52% for the last 200 days.
Analysts’ Opinion of NMRA
Many brokerage firms have already submitted their reports for NMRA stocks, with RBC Capital Mkts repeating the rating for NMRA by listing it as a “Sector Perform.” The predicted price for NMRA in the upcoming period, according to RBC Capital Mkts is $4 based on the research report published on January 02, 2025 of the current year 2025.
JP Morgan, on the other hand, stated in their research note that they expect to see NMRA reach a price target of $15, previously predicting the price at $18. The rating they have provided for NMRA stocks is “Neutral” according to the report published on November 05th, 2024.
H.C. Wainwright gave a rating of “Buy” to NMRA, setting the target price at $30 in the report published on October 01st of the previous year.
NMRA Trading at -59.86% from the 50-Day Moving Average
After a stumble in the market that brought NMRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.52% of loss for the given period.
Volatility was left at 6.67%, however, over the last 30 days, the volatility rate increased by 7.04%, as shares sank -18.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -84.79% lower at present.
During the last 5 trading sessions, NMRA fell by -12.78%, which changed the moving average for the period of 200-days by -82.92% in comparison to the 20-day moving average, which settled at $1.7530. In addition, Neumora Therapeutics Inc saw -85.19% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NMRA starting from BERNS PAUL L, who sale 13,871 shares at the price of $1.69 back on Feb 18 ’25. After this action, BERNS PAUL L now owns 7,405,004 shares of Neumora Therapeutics Inc, valued at $23,468 using the latest closing price.
Milligan Michael Lee, an insider of Neumora Therapeutics Inc, sale 1,978 shares at $1.69 during a trade that took place back on Feb 18 ’25, which means that Milligan Michael Lee is holding 22,470 shares at $3,351 based on the most recent closing price.
Stock Fundamentals for NMRA
The total capital return value is set at -0.98. Equity return is now at value -70.48, with -65.46 for asset returns.
Based on Neumora Therapeutics Inc (NMRA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -67.04.
Currently, EBITDA for the company is -187.53 million with net debt to EBITDA at 0.91. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.98.
Conclusion
In conclusion, Neumora Therapeutics Inc (NMRA) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
